目的 觀察米非司酮治療子宮肌瘤的臨床療效及安全性。方法 對(duì)2011年9月—2012年12月天津市中心婦產(chǎn)科醫(yī)院收治的48例子宮肌瘤患者，從月經(jīng)開始的3～5 d，睡前口服米非司酮10 mg/d，3個(gè)月為一個(gè)療程，堅(jiān)持服用一個(gè)療程。檢測(cè)患者治療前、后子宮及肌瘤的體積，抽血測(cè)定血清中雌激素和孕酮的水平。結(jié)果 治療后患者的子宮及肌瘤體積、血清激素及孕酮水平與治療前相比差異均有顯著性（P＜0.05）。結(jié)論 采用米非司酮治療子宮肌瘤可有效減少血清雌、孕激素水平，能縮小子宮及肌瘤的大小，對(duì)子宮肌瘤癥狀有較好的療效。

Objective To evaluate the clinical efficacy and safety of mifepristone in the treatment of uterine fibroids. Methods The patients (48 cases) with uterine fibroids in September, 2011 to December, 2012 in Tianjin Central Obstetrics and Gynecology Hospital were retrospectively analyzed. The patients were po administered with mifepristone (10 mg/d) before bedtime from menstruation began to 3—5 d. Three months was as one course, and they were treated for one course. Uterine and fibroid volume, levels of estrogen and progesterone in serum were measured before and after the treatment. Results Uterine and fibroid volume, serum hormones and progesterone levels were of significant difference compared with those before the treatment (P < 0.05). Conclusion The usage of mifepristone in the treatment of uterine myoma could effectively reduce the estrogen and progesterone levels in serum, and could reduce the size of uterus and myoma, which has the good effect on uterine symptoms of uterine fibroid.